Crescent Capital Consulting’s Pfizer PFE Stock Holding History

Crescent Capital Consulting’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$4.24M	Buy	71,672 +7,627	+12%	+$378K	0.7%	34
2021 Q3	$2.75M	Buy	64,045 +3	+0%	+$133	0.51%	49
2021 Q2	$2.51M	Sell	64,042 -718	-1%	-$27.9K	0.47%	52
2021 Q1	$2.35M	Buy	64,760 +24,737	+62%	+$878K	0.51%	52
2020 Q4	$1.48M	Buy	+40,023	New	+$1.47M	0.38%	62

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Crescent Capital Consulting's PFE Position: Q4 2021 in Review

Crescent Capital Consulting increased its Pfizer (PFE) stake by 12% in Q4 2021, buying an estimated $378K and bringing the position to 71,672 shares worth $4.24M. The position accounts for 0.7% of the portfolio, ranked #34.

Crescent Capital Consulting first reported a position in PFE in Q4 2020 and has held it in 5 quarters since. 3,262 funds tracked by Wall St. Rank hold PFE as of Q4 2021.

Crescent Capital Consulting held 71,672 shares of Pfizer worth $4.24M as of Q4 2021.
Crescent Capital Consulting bought 7,627 Pfizer shares in Q4 2021, an estimated $378K.
Pfizer made up 0.7% of Crescent Capital Consulting's portfolio in Q4 2021, its #34 holding.
Crescent Capital Consulting first reported a position in Pfizer in Q4 2020 and has held it in 5 quarters since.
3,262 funds tracked by Wall St. Rank held Pfizer as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.